Saladax Signs on InyDia Labs to Distribute My5-FU in Spain, Portugal | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Saladax today announced a deal with InyDia Labs for the distribution of the My5-FU test in Spain and Portugal.

Saladax's My5-FU test measures levels of the oncology drug 5-fluorouracil, or 5-FU, in the blood of cancer patients, and the deal with InyDia makes it the exclusive provider of My5-FU test kits in the two countries.

Financial terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.